Eisai (ESAIY) and Biogen (BIIB) announced that lecanemab-irmb subcutaneous injection, or Leqembi Iqlik, is now available in the U.S. as a maintenance dosing regimen for the treatment of Alzheimer’s disease in patients with Mild Cognitive Impairment or mild dementia stage of disease.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Eisai, Biogen announce U.S. availability of LEQEMBI IQLIK
- Biogen price target raised to $167 from $142 at BofA
- Citizens JMP healthcare analysts hold an analyst/industry conference call
- Eisai, Biogen announce LEQEMBI approved by NMPA in China
- Freeport-McMoRan, Biogen, Intel, Uranium Energy, CME Trending by Analysts